Home
Resources
Publications
Incorporation of Antibiotics in Liposomes Designed for Tuberculosis Therapy by Inhalation

Incorporation of Antibiotics in Liposomes Designed for Tuberculosis Therapy by Inhalation

Oselys R Justo, Angela M Moraes

Drug Deliv. Jul-Sep 2003;10(3):201-7.

PMID: 12944141

Abstract:

Liposomal encapsulation of tuberculostatic drugs can potentially increase their therapeutic index. The incorporation of isoniazid, pyrazinamide, rifampicin, ethionamide, and streptomycin in extruded distearoylphosphatidylcholine/cholesterol liposomes designed for administration through inhalation was evaluated. Ethionamide and rifampicin were incorporated during lipid film formation, whereas solutions of the remaining drugs were used to hydrate preformed lipid bilayers. Final drug to lipid ratios around 0.3 were achieved for isoniazid and pyrazinamide, and mean vesicle diameters varied from 286 to 329 nm. No expressive drug leakage or mean vesicle diameter changes occurred during 3 weeks. No significant incorporation was achieved for streptomycin, ethionamide, and rifampicin.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
ALP3810740	Streptomycin sesquisulfate hydrate		3810-74-0 (anhydrous)	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: